Ritonavir-boosted protease inhibitors in HIV therapy

Annals of Medicine

Volumn 43, Issue 5, 2011, Pages 375-388

  Hull, Mark W ^a   Montaner, Julio S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antiretroviral therapy; HIV; protease inhibitors; ritonavir

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FOSAMPRENAVIR PLUS RITONAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; ZIDOVUDINE;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DYSLIPIDEMIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC DISORDER; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; RITONAVIR;

EID: 79959359682     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.572905     Document Type: Article

References (131)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-60. (Pubitemid 28135961)
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450-4. (Pubitemid 28082255)
3. Prasad VR, Goff SP. Structure-function studies of HIV reverse transcriptase. Ann N Y Acad Sci. 1990;616:11-21.
4. Copeland TD, Oroszlan S. Genetic locus, primary structure, and chemical synthesis of human immunodeficiency virus protease. Gene analysis techniques. 1988;5:109-15. (Pubitemid 19008846)
5. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA. 1988;85:4686-90.
6. Rose JR, Craik CS. Structure-assisted design of nonpeptide human immunodeficiency virus-1 protease inhibitors. Am J Respir Crit Care Med. 1994;150(6 Pt 2):S176-82. (Pubitemid 24364345)
7. Goff SP. Retroviral reverse transcriptase: synthesis, structure, and function. J Acquir Immune Defic Syndr. 1990;3:817-31. (Pubitemid 20280610)
8. Tartaglione TA, Collier AC. Development of antiviral agents for the treatment of human immunodeficiency virus infection. Clin Pharm. 1987;6:927-40. (Pubitemid 18007444)
9. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337:725-33. (Pubitemid 27417971)
10. Montaner JS, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA. 1998;279:930-7. (Pubitemid 28136082)
11. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304: 321-33.
12. Robins T, Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr. 1993;6:162-70. (Pubitemid 23082870)
13. Winslow DL, Otto MJ. HIV protease inhibitors. AIDS. 1995;9 Suppl A:S183-92.
14. Rodes B, Sheldon J, Toro C, Jimenez V, Alvarez MA, Soriano V. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother. 2006;57:709-13.
15. Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008;71:298-305. (Pubitemid 351347797)
16. Desbois D, Roquebert B, Peytavin G, et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob Agents Chemother. 2008;52:1545-8. (Pubitemid 351522031)
17. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008;47:266-85. (Pubitemid 351920631)
18. Noble S, Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 1996;52:93-112.
19. Schapiro JM, Winters MA, Stewart F, et al. The effect of highdose saquinavir on viral load and CD4+ T-cell counts in HIVinfected patients. Ann Intern Med. 1996;124(2):1039-50.
20. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996;334:1011-7. (Pubitemid 26124452)
21. Kirk O, Mocroft A, Pradier C, et al. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir. AIDS. 2001;15:999-1008. (Pubitemid 32476667)
22. Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis. 2003;188:635-42. (Pubitemid 37115175)
23. Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther. 2005;10:735-43. (Pubitemid 41376853)
24. Kurowski M, Sternfeld T, Sawyer A, Hill A, Mocklinghoff C. Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers. HIV Med. 2003;4:94-100. (Pubitemid 36582291)
25. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr. 2009;50:367-74.
26. Hoetelmans RM, Meenhorst PL, Mulder JW, Burger DM, Koks CH, Beijnen JH. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir. Pharm World Sci. 1997;19:159-75. (Pubitemid 27368196)
27. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:734-9. (Pubitemid 27417972)
28. Berns JS, Cohen RM, Silverman M, Turner J. Acute renal failure due to indinavir crystalluria and nephrolithiasis: report of two cases. Am J Kidney Dis. 1997;30:558-60. (Pubitemid 27422304)
29. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119-25. (Pubitemid 27337395)
30. Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother. 1999;33:325-39. (Pubitemid 29157745)
31. Kurowski M, Kaeser B, Sawyer A, Popescu M, Mrozikiewicz A. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther. 2002;72:123-32. (Pubitemid 35034490)
32. Markowitz M, Conant M, Hurley A, et al. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection. J Infect Dis. 1998;177:1533-40. (Pubitemid 28243576)
33. Saag MS, Tebas P, Sension M, et al. Randomized, doubleblind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511). AIDS. 2001;15: 1971-8. (Pubitemid 32980639)
34. Robbins GK, De Gruttola V, Shafer RW, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2293-303. (Pubitemid 37509737)
35. Shafer RW, Smeaton LM, Robbins GK, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med. 2003;349:2304-15. (Pubitemid 37509738)
36. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-46. (Pubitemid 34680595)
37. Moyle GJ, Youle M, Higgs C, et al. Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus. J Clin Pharmacol. 1998;38:736-43. (Pubitemid 28388224)
38. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA. 1995;92:2484-8.
39. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35:275-91. (Pubitemid 28491214)
40. Ng J, Klein CE, Causemaker SJ, et al. A comparison of the single dose bioavailability of a ritonavir tablet formulation relative to the soft gelatin capsule in healthy adult subjects. Abstract TUPE 0076. In: XVII International AIDS Conference. Mexico City, Mexico, 3-8 August, 2008.
41. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med. 1995;333: 1528-33.
42. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 1995;333:1534-9.
43. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet. 1998;351:543-9. (Pubitemid 28077559)
44. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr. 2002;29 Suppl 1:S11-8. (Pubitemid 34163468)
45. Becker SL. The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs. 2003;12:401-12. (Pubitemid 36336411)
46. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet. 2002;359:30-6. (Pubitemid 34119193)
47. Van der Sandt IC, Vos CM, Nabulsi L, et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS. 2001; 15:483-91. (Pubitemid 32207568)
48. Olson DP, Scadden DT, D' Aquila RT, De Pasquale MP. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS. 2002;16:1743-7.
49. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother. 2004;53: 4-9. (Pubitemid 38072176)
50. Scott JD. Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviralexperienced patients. Am J Health Syst Pharm. 2005;62: 809-15. (Pubitemid 40547364)
51. Youle M. Overview of boosted protease inhibitors in treatment- experienced HIV-infected patients. J Antimicrob Chemother. 2007;60:1195-205. (Pubitemid 350176278)
52. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-24. (Pubitemid 28553744)
53. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos. 1999;27:902-8. (Pubitemid 29347590)
54. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003;63: 769-802. (Pubitemid 36432083)
55. Oldfield V, Plosker GL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2006; 66:1275-99. (Pubitemid 44055872)
56. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007;44:401-10. (Pubitemid 46555374)
57. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviralnaive adults with HIV-1 infection: 48-week results. AIDS. 2001;15:F1-9. (Pubitemid 32055772)
58. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment- naive patients: 4 year follow-up study. AIDS. 2004;18: 775-9. (Pubitemid 38535005)
59. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106. (Pubitemid 351679596)
60. Sierra-Madero J, Villasis-Keever A, Mendez P, et al. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV treatment-naive subjects with CD4+ 200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr. 2010;53:582-8.
61. Eron JJ, Feinberg J, Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIVpositive patients: a 48-week randomized clinical trial. J Infect Dis. 2004;189:265-72. (Pubitemid 38147251)
62. Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43:153-60. (Pubitemid 44454808)
63. Flexner C, Tierney C, Gross R, et al. Comparison of oncedaily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010;50:1041-52.
64. Gathe J, da Silva BA, Cohen DE, et al. A once-daily lopinavir/ ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviralnaive subjects through 48 weeks. J Acquir Immune Defic Syndr. 2009;50:474-81.
65. St Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 1996;29:53-6. (Pubitemid 26096373)
66. Murphy RL, Gulick RM, DeGruttola V, et al. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis. 1999;179:808-16. (Pubitemid 29159325)
67. Haubrich R, Thompson M, Schooley R, et al. A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team. AIDS. 1999;13:2411-20.
68. Nadler JP, Gathe JC, Pollard RB, et al. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients. BMC Infect Dis. 2003;3:10.
69. Arvieux C, Tribut O. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. Drugs. 2005;65:633-59. (Pubitemid 40477784)
70. Furfine ES, Baker CT, Hale MR, et al. Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir. Antimicrob Agents Chemother. 2004; 48:791-8. (Pubitemid 38280326)
71. Wood R, Arasteh K, Stellbrink HJ, et al. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients. Antimicrob Agents Chemother. 2004; 48:116-23. (Pubitemid 38040186)
72. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:22-32. (Pubitemid 38044778)
73. MacManus S, Yates PJ, Elston RC, White S, Richards N, Snowden W. GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS. 2004;18:651-5. (Pubitemid 38393464)
74. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-82. (Pubitemid 44160731)
75. Flamholc L, Gisslen M. Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naive patients. Ther Clin Risk Manag. 2008;4:1281-4.
76. Hicks CB, DeJesus E, Sloan LM, et al. Comparison of oncedaily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses. 2009;25:395-403.
77. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol. 2007;30:79-88. (Pubitemid 46984112)
78. Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005;44:1035-50. (Pubitemid 41356390)
79. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004;48:2091-6. (Pubitemid 38691603)
80. Von Hentig N, Dauer B, Haberl A, et al. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults. Eur J Clin Pharmacol. 2007;63:935-40. (Pubitemid 47387910)
81. Molto J, Santos JR, Valle M, et al. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIVinfected patients in routine clinical practice. Ther Drug Monit. 2007;29:648-51. (Pubitemid 47494066)
82. Rodriguez Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C- T polymorphism at the multidrug resistance gene 1. Clin Infect Dis. 2006;42:291-5. (Pubitemid 43054206)
83. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a doseranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29. (Pubitemid 36091481)
84. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003;17:2603-14. (Pubitemid 38402338)
85. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Oncedaily atazanavir/ritonavir versus twice-daily lopinavir/ ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646-55.
86. Smith KY, Weinberg WG, Dejesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5.
87. Squires K, Lazzarin A, Gatell JM, et al. Comparison of oncedaily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004;36:1011-9. (Pubitemid 38989366)
88. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361:2230-40.
89. Daar ES, Tierney C, Fischl MA, et al. ACTG 5202: Final results of ABC/3TC or TDF/FTC with either EFV or ATV/r in treatment-naive HIV-infected patients. Abstract 59LB. In: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 2010.
90. Soriano V, Koppe S, Migrone H, et al. Prospective randomized comparison of nevirapine and atazanavir/ritonavir both combined with tenofovir DF/emtricitabine in treatment- naive HIV-1 infected patients: ARTEN study week 48 results. Abstract LBPEB07. 5th IAS Conference on HIV Treatment and Pathogenesis. Cape Town, South Africa, 19-22 July 2009.
91. Gatell J, Salmon-Ceron D, Lazzarin A, et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis. 2007;44:1484-92. (Pubitemid 46801594)
92. Squires KE, Young B, Dejesus E, et al. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010;24:2019-27.
93. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi- PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47:3123-9. (Pubitemid 37229567)
94. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-21. (Pubitemid 40734460)
95. Dierynck I, De Wit M, Gustin E, et al. Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol. 2007;81:13845-51. (Pubitemid 350247878)
96. McKeage K, Perry CM, Keam SJ. Darunavir: a review of its use in the management of HIV infection in adults. Drugs. 2009;69:477-503.
97. Katlama C, Esposito R, Gatell JM, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21: 395-402.
98. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-18. (Pubitemid 46568621)
99. Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169-78. (Pubitemid 46541620)
100. Molina JM, Cohen C, Katlama C, et al. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment- experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr. 2007;46:24-31. (Pubitemid 47514614)
101. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir- ritonavir at 48 weeks in treatment-experienced, HIVinfected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49-58. (Pubitemid 47023100)
102. Cahn P, Fourie J, Grinsztejn B, et al. Efficacy and safety at 48 weeks of once-daily vs twice-daily DRV/r in treatmentexperienced HIV-1 patients with no DRV resistance associated mutations: the ODIN Trial. Abstract 57. Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA, 16-19 February 2010.
103. Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22:1389-97.
104. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009; 23:1679-88.
105. Poppe SM, Slade DE, Chong KT, et al. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother. 1997;41:1058-63. (Pubitemid 27194185)
106. Back NK, van Wijk A, Remmerswaal D, et al. In-vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS. 2000;14:101-2. (Pubitemid 30072090)
107. MacGregor TR, Sabo JP, Norris SH, Johnson P, Galitz L, McCallister S. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin Trials. 2004;5:371-82. (Pubitemid 40253637)
108. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatmentexperienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised openlabel trials. Lancet. 2006;368:466-75. (Pubitemid 44142769)
109. Graff J, von Hentig N, Kuczka K, et al. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrob Chemother. 2008;61:394-9.
110. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, openlabel, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40:280-7. (Pubitemid 41533067)
111. Pulido F, Arribas JR, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1-9.
112. Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis. 2008;198:234-40. (Pubitemid 352019289)
113. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS. 2009;23:279-91.
114. Arribas JR, Horban A, Gerstoft J, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24:223-30.
115. Katlama C, Valantin MA, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24: 2365-74.
116. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296:806-14. (Pubitemid 44223104)
117. Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr. 2007;44:417-22. (Pubitemid 46555376)
118. Vernazza P, Daneel S, Schiffer V, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir- Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007;21:1309-15. (Pubitemid 46883485)
119. Gutmann C, Cusini A, Gunthard HF, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24:2347-54.
120. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, Churchill DR. Cushing ' s syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fl uticasone. Sex Transm Infect. 1999; 75:274. (Pubitemid 29420123)
121. Clevenbergh P, Corcostegui M, Gerard D, et al. Iatrogenic Cushing ' s syndrome in an HIV-infected patient treated with inhaled corticosteroids (fl uticasone propionate) and low dose ritonavir enhanced PI containing regimen. J Infect. 2002;44:194-5. (Pubitemid 36104775)
122. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep. 2009;58(RR-4):1-207; quiz CE1-4.
123. Yeh RF, Lipman BA, Mayberry C, Miguel B, Nemecek JJ, Gathe JC Jr. Lopinavir/ritonavir dosage form affects quality of life during monotherapy in HIV-positive adults. J Int Assoc Physicians AIDS Care (Chic). 2010;9:273-7.
124. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 1998;351:871-5. (Pubitemid 28121176)
125. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. ' Buffalo hump ' in men with HIV-1 infection. Lancet. 1998;351:867-70. (Pubitemid 28121175)
126. Noor MA. The role of protease inhibitors in the pathogenesis of HIV-associated insulin resistance: cellular mechanisms and clinical implications. Curr HIV/AIDS Rep. 2007;4:126-34. (Pubitemid 47493053)
127. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs
128. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis. 2010;201:318-30.
129. FDA notifications. Potential serious effect of combination saquinavir-ritonavir. AIDS Alert. 2010;25:45-6.
130. Clumeck N, Dedes N, Pozniak A, et al.; European AIDS Clinical Society. Guidelines: clinical management and treatment of HIV-infected adults in Europe. Version 5.2. 2009. Available at: http://www.europeanaidsclinicalsociety.org/ guidelines.asp (accessed 13 January 2011).
131. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services; 1 December 2009; 1-161. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdole scentGL.pdf (accessed 18 October 2010).